Clinical Trial Update: The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on SPARC, evaluating stereotactic prostate ablative radiotherapy using the CyberKnife device for prostate cancer. Status: UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Prostate Cancer | Phase 2 | Status: UNKNOWN